Debiopharm continues the fight against antibiotic resistance with investment in ABAC Therapeutics Inc.
ABAC develops new targeted antibiotics for patients with severe infections
Lausanne, Switzerland – February 15, 2018 – Debiopharm Group ™ announces an investment in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics Inc. This investment was made through the Debiopharm Innovation Fund, its strategic investment fund, and illustrates the synergy between the group companies in the fight against the worrying emergence of antibiotic resistance.
Full PR available here